Log in

OTCMKTS:ABLYF - Ablynx Stock Price, Forecast & News

0.00 (0.00 %)
(As of 04/30/2019)
Today's Range
Now: $50.63
50-Day Range
MA: $50.63
52-Week Range
Now: $50.63
Average VolumeN/A
Market Capitalization$3.81 billion
P/E RatioN/A
Dividend YieldN/A
Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Previous SymbolNASDAQ:ABLYF



Sales & Book Value

Annual Sales$62.73 million
Book Value$2.71 per share



Market Cap$3.81 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive ABLYF News and Ratings via Email

Sign-up to receive the latest news and ratings for ABLYF and its competitors with MarketBeat's FREE daily newsletter.

Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions

What is Ablynx's stock symbol?

Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."

Has Ablynx been receiving favorable news coverage?

News articles about ABLYF stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ablynx earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Ablynx.

Who are some of Ablynx's key competitors?

What other stocks do shareholders of Ablynx own?

Who are Ablynx's key executives?

Ablynx's management team includes the folowing people:
  • Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
  • Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
  • Mr. Piet Houwen, Chief Operations Officer
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer
  • Lies Vanneste, Director of Investor Relations

How do I buy shares of Ablynx?

Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ablynx's stock price today?

One share of ABLYF stock can currently be purchased for approximately $50.63.

How big of a company is Ablynx?

Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year. View Additional Information About Ablynx.

What is Ablynx's official website?

The official website for Ablynx is http://www.ablynx.com/.

How can I contact Ablynx?

Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000.

MarketBeat Community Rating for Ablynx (OTCMKTS ABLYF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  326 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel